Bioclinica Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$176,790	16
2023	Research	$5,340	1
2022	Research	$915,085	10
2021	Research	$1,681,240	72
2020	Research	$1,509,635	23
2019	Research	$17,096	37

Breakdown

Who paid Research payments · program years 2019–2025

Biogen, Inc. $3,935,510 29 payments
Eisai Inc. $335,436 84 payments
ACADIA Pharmaceuticals Inc $29,423 5 payments
Boehringer Ingelheim RCV GmbH & Co KG $4,316 39 payments
Pfizer Inc. $501 2 payments

Studies the money was for Research payments · program years 2019–2025

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $2,126,664 6 payments
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $768,229 2 payments
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $296,666 4 payments
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease $258,473 1 payment
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $176,790 16 payments
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $158,646 68 payments
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease $133,594 2 payments
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect of Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation $94,048 2 payments
Long-Term Evaluation of BIIB067 $64,979 2 payments
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease $57,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.